New drug promising for psoriatic arthritis

Article

An oral phosphodiesterase 4 inhibitor may offer significant improvement in signs and symptoms of psoriatic arthritis, according to preliminary trial data.

Related Videos
Related Content

Evaluating Efficacy of Trifarotene in Latin American Patients With Acne

September 30th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Understanding Eyebrow and Eyelash Hair Loss in Severe Alopecia Areata

September 29th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Data-Driven Advice for Health Care Workers Experiencing Contact Dermatitis

September 29th 2023

Prolonged Remission in Rosacea: A Breakthrough With Subantibiotic Dose of Oral Doxycycline

September 29th 2023

Evaluating Efficacy of Trifarotene in Latin American Patients With Acne

September 30th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Understanding Eyebrow and Eyelash Hair Loss in Severe Alopecia Areata

September 29th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Data-Driven Advice for Health Care Workers Experiencing Contact Dermatitis

September 29th 2023

Prolonged Remission in Rosacea: A Breakthrough With Subantibiotic Dose of Oral Doxycycline

September 29th 2023

Evaluating Efficacy of Trifarotene in Latin American Patients With Acne

September 30th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Understanding Eyebrow and Eyelash Hair Loss in Severe Alopecia Areata

September 29th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Data-Driven Advice for Health Care Workers Experiencing Contact Dermatitis

September 29th 2023

Prolonged Remission in Rosacea: A Breakthrough With Subantibiotic Dose of Oral Doxycycline

September 29th 2023
© 2023 MJH Life Sciences

All rights reserved.